ArticleJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2026
From trial to practice: early multicenter real-world experience with the circular pulsed field ablation catheter.
Article in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe PulseSelect™ circular pulsed field ablation (PFA) catheter demonstrated excellent safety in its pivotal trial, but real-world evidence on its early adoption and implementation remains scarce.
objectiveTo report the first multicentre, real-world experience of atrial fibrillation (AF) ablation with the PulseSelect circular PFA catheter, focusing on procedural characteristics, metrics, safety and short-term clinical outcomes.
methodsThis observational study included the first 520 consecutive patients undergoing AF ablation with the PulseSelect catheter across five Spanish centres. Patient and procedural characteristics, safety (major complications), acute pulmonary vein isolation (PVI) rate and arrhythmia recurrence during follow-up were recorded.
resultsAcute PVI was achieved in 518/520 patients (99.6%). Procedures were performed under deep sedation (52.7%) or general anaesthesia (47.3%), without anaesthesia-related complications. Mean procedural time was 69.95 min, with a learning curve plateauing after the first 8-10 cases. Same-day or < 24 h discharge occurred in 95.4%. Major complications occurred in four patients (0.76%); no deaths or clinically evident haemolysis were observed. Electroanatomical mapping (EAM) was used in a minority of cases (3.65%); when used, there was 100% concordance between post-ablation maps and PulseSelect catheter recordings in confirming PVI. During a mean follow-up of 10.8 ± 5 months, arrhythmia recurrence after the 3-month blanking period occurred in 16.2% of patients. After one year of follow-up, arrhythmic recurrence was observed in 52/220 (23.63%) patients.
conclusionsIn the first large real-world series, AF ablation with the PulseSelect circular PFA catheter without routine use of EAM was feasible, safe, and effective, with major complications < 1% and short hospitalisation. These findings support rapid and safe implementation of this technology in clinical practice, with flexibility regarding anaesthesia modality.
Identifiers
42536270What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.